Heat Biologics’ Stock Gains 12.58% Amid COVID-19 Vaccine Development

Since the major lockdown Heat Biologics’ (NASDAQ: HTBX) stock has been rising from $0.47 to $0.84 although on March 5 it reached $0.97 that was a peak price of this year. From the IPO till these days the biotech company has not shown positive earnings and been raising funds by issuing shares and taking on debts. The COVID-19 has unveiled new opportunities to many biotech firms in raising funds for battling the global pandemic. Now they are in a big race to create an effective vaccine for the trouble maker to the respiratory system of the millions of victims.

Even though its financial standings are not so good optimistic investors still have a hope that HTBX could repeat the fate of AMZN.

[the_ad id=”4924″]

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life